Sodium glucose transporter 2 inhibitors for heart failure

Read full text Summarise with VIRAT
Authors: Daisuke Usuda, Daiki Furukawa, Ryo Imaizumi, Rikuo Ono, Yuki Kaneoka, Eri Nakajima, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Riki Sakurai, Kenji Kawai
+15 more Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou, Sakurako Ito, Kentaro Mishima, Akihiko Kondo, Keiko Mizuno, Hiroki Takami, Takayuki Komatsu, Tomohisa Nomura, Manabu Sugita
Cited by: 0
References: 101

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Heart failure (HF) is a leading cause of cardiovascular morbidity and mortality, affecting over 64 million individuals worldwide. Despite advances in guideline-directed medical therapy, patients with HF continue to experience poor outcomes, highlighting the need for novel therapeutic approaches. Sodium glucose transporter 2 (SGLT2) inhibitors, initially developed for diabetes management, have emerged as groundbreaking therapies for HF. These agents demonstrate remarkable cardiovascular benefits that extend beyond their glucose-lowering effects, including significant reductions in HF hospitalization and cardiovascular mortality rates. Landmark trials including Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure, Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced Ejection Fraction, Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction, and Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure have established the efficacy of SGLT2 inhibitors across the spectrum of HF phenotypes, regardless of diabetes status. The mechanisms underlying these benefits are multifaceted, involving improvements in cardiac energetics, mitochondrial function, reduction of oxidative stress, attenuation of inflammation, and favorable effects on cardiac remodeling and fibrosis. This comprehensive review examines the current evidence supporting the use of SGLT2 inhibitors in HF management, explores the mechanistic pathways responsible for their cardiovascular benefits, analyzes key clinical trial data, and discusses future prospects for this transformative drug class in cardiovascular medicine.

Fields of Study & Subjects

Heart Failure Treatment and Management Diabetes Treatment and Management Cardiovascular Function and Risk Factors

Publication details

Journal / source
World Journal of Cardiology
Volume
18
Issue
3
Publication date
23 March 2026
Language
EN